Progress of GlycoMimetics, Inc.’s Novel Compounds Highlighted at 2011 Annual Meeting of the American Society of Hematology

GAITHERSBURG, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (GMI), a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that its collaborators delivered three oral presentations at the 2011 Annual Meeting of the American Society of Hematology (ASH). The presentations highlighted data on GMI-1070, GMI’s lead investigational compound for the treatment of vaso-occlusive crises associated sickle cell disease which is under an exclusive worldwide licensing agreement with Pfizer Inc. (NYSE:PFE), as well as data from a novel family of compounds being developed to treat AML and other cancers.

Back to news